The global microbiomes market is forecasted to reach US$9,376 million in 2024, growing at a CAGR of 135.47% for the period spanning 2018-2024. The factors such as growing geriatric population, rising personal healthcare expenditures, increasing chronic diseases incidence, accelerating personal disposable income and improving consumer confidence index are expected to drive the market. However, growth of the industry would be challenged by intellectual property issues, stringent regulatory framework and manufacturing and technology considerations. Few notable trends include progressing product pipeline, increasing product licensing contracts and inclining microbiome research and development activities. In 2020, the outbreak of COVID-19 pandemic has created a favorable impact on the market as the microbiomes-based products sales increased.
The global microbiomes market can be split on the basis of applications into drugs and diagnostics. Currently, drugs occupies the higher share owing to growth in acceptance of probiotics among population and rising prevalence of autoimmune diseases, cancer and gastrointestinal diseases.
The fastest growing regional market is North America owing to rising incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in human microbiome along with next-generation sequencing.
Scope of the report:
• The report provides a comprehensive analysis of the global microbiomes market, segmented into drugs and diagnostics. • The major regional markets (North America, Europe and Asia-Pacific) have been analysed. • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth. • The competitive landscape of the market, along with the company profiles of leading players (Seres Therapeutics, Inc., Synthetic Biologics, Inc., Evelo Biosciences, Inc., 4D Pharma Plc, Infant Bacterial Therapeutics AB and Takeda Pharmaceutical Company Limited) are also presented in detail.
Key Target Audience:
• Microbiome-based Manufacturers • End Users • Consulting Firms • Investment Banks • Government Bodies & Regulating Authorities
Our reports have been used by over 10K customers, including:
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
280 pages •
By Prescient & Strategic Intelligence Private Limited
• Mar 2021
Precision Medicine Market Research Report: By Type (Therapeutics, Diagnostics, Personalized Medical Care) - Global Industry Analysis and Growth Forecast to 2030
In July 2019, U.S. president Donald Trump decided to bring down the prices of drugs in the country to make them equal or similar to the international rates....
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
The global injectables market is estimated to reach US$759.61 billion in 2025, progressing at a CAGR of 10.95%, over the period 2021-2025. Factors such as increasing geriatric population, upsurge in demand for convenient drug delivery, expanding use of biologics, rising healthcare expenditure and surging incidence of cancer cases would drive...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
Patent protected: Many industry operators are expected to raise prices on widely used specialty drugs Abstract Brand Name Pharmaceutical Manufacturing in the US Over the five years to 2019, the Brand Name Pharmaceutical Manufacturing industry in the United States experienced several new drug launches,...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
257 pages •
By The Business Research Company
• Dec 2020
Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications And Growth provides the strategists, marketers and senior management with the critical information they need to assess the global anti-viral drug therapy market. Description: Where is the largest and fastest growing...
The global API market is forecasted to reach US$270.83 billion in 2024, growing at a CAGR of 6.5% for the period spanning 2020-2024. The factors such as increasing ageing population, rising healthcare expenditure per capita, growing cancer patients, inclining orphan drugs industry and accelerating outsourcing of API drugs are expected to drive...
The addictions therapeutics market was valued at 6,691.01 million in 2019 and is projected to reach US$ 10,735.94 million by 2027; it is expected to grow at a CAGR of 6.2% from 2020 to 2027. Rising addiction among the general populace and increasing awareness campaigns are among the major factors fueling the growth of the market. Moreover,...
Alcohol Excessive Use
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.